Search

everythinglearnresearchcommunity

for

Search:↓

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

Using a combination of finasteride, minoxidil, dermarolling, and RU58841 to treat hair loss. Participants discussed the time commitment required for treatment and the effectiveness of different dosages.

The conclusion of this conversation is that the user experienced hair regrowth and increased overall hair thickness after using dutasteride and derma pen treatments for 5 years. They did not experience any side effects.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

The user is experiencing ongoing hair loss despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, cyproterone acetate, transdermal estradiol, and topical bicalutamide. They suspect cyproterone acetate may be worsening their hair loss and are considering switching to injection monotherapy.

The conversation discusses the progress and potential of hair cloning by Stemson Therapeutics, questioning if it will be realized in the next 5-10 years or if it's just false hope. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

A 24-year-old with hair thinning is using a regimen including dutasteride, RU58841, HGH, GHK-cu, and other compounds to protect and regrow hair. They are also incorporating a mild cutting cycle with testosterone propionate, anavar, and tirzepatide.

The user has been using Finasteride for hair loss and is considering adding alphatradiol, stemoxydine, or 2% minoxidil to their regimen. They are concerned that stemoxydine, which shortens the resting phase of hair, might accelerate hair loss in those not using Finasteride by depleting hair cycles without strengthening miniaturized hairs.

Topical minoxidil may cause skin aging effects like wrinkles and dark circles, possibly due to its alcohol content, while oral finasteride is reported to make users look younger. Switching to oral minoxidil or using moisturizers might help reduce these skin issues.

The user has been using finasteride for hair loss and is considering adding RU58841. They ask about RU58841's effectiveness, potential heart side effects, duration of action, dosage increase over time, transitioning to GT20029, and where to find the liquid form.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.

The conversation discusses hair loss treatments, specifically using 5% minoxidil foam, Vitamin B12, and Vitamin D, with suggestions to add oral finasteride and minoxidil for better results. Concerns about side effects, particularly from finasteride, and the need for a DHT blocker are also highlighted.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

A 20-year-old lost significant hair after one year of treatment, using minoxidil, finasteride, and later dutasteride. They are considering adding RU58841 but are advised to return to finasteride and minoxidil for a year before deciding.

A user shared their experience using 5% minoxidil twice daily, 1 mg finasteride daily, and weekly derma stamping for hair loss, noting no crown thinning but front diffuse thinning and hairline issues. They experienced fewer side effects on 0.5 mg finasteride but returned to 1 mg, and did not experience shedding after starting treatment.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

The conversation discusses using GHK-Cu, C60, and saw palmetto oil as treatments for hair loss. Specific treatments mentioned include Minoxidil (Min), Finasteride (Fin), and RU58841 (RU).

The user is seeking advice on maximizing hair growth while using oral finasteride, topical minoxidil, Nizoral, and microneedling, and is considering adding a laser diode cap, topical finasteride, retinol, and caffeine. Suggestions include using tretinoin with minoxidil for better absorption, switching to dutasteride, and considering RU58841 or pyrilutamide.

Using topical finasteride with creatine might help reduce hair loss by targeting local DHT while maintaining normal systemic levels, but results are uncertain without testing. Users report mixed experiences with topical treatments like finasteride, dutasteride, RU58841, and minoxidil, with some seeing regrowth and others experiencing side effects.

User shared before and after photos of hair regrowth using Dutasteride 5x a week for 19 months. They experienced significant improvement and thanked others for their support.

The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It also mentions ongoing human trials for hair multiplication/cloning at Yokohama National University, with skepticism about the timeline.

The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.

The user experienced significant hair regrowth after 5 months using finasteride, dutasteride, and oral minoxidil, despite initial side effects like erectile dysfunction, which resolved after switching from finasteride to dutasteride. The user reports full recovery of hair density and improved skin condition, though the right temple remains slightly recessed.

A 21-year-old has been using a 0.5 mm dermaroller weekly with 5% Minoxidil for five months and Finasteride for three months to address hair loss. The conversation includes questions about the frequency of dermarolling.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

The conversation discusses a hair loss treatment involving a hair transplant of approximately 2500 grafts to the frontal area, daily use of finasteride, twice-daily topical minoxidil, and daily caffeine shampoo since the hair transplant procedure. One person is skeptical about the improvement in the crown area with just finasteride and minoxidil.